Lexicon Pharmaceuticals
LXRX
110 hedge funds and large institutions have $479M invested in Lexicon Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 38 increasing their positions, 29 reducing their positions, and 10 closing their positions.
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
31% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 29
15% more funds holding
Funds holding: 96 → 110 (+14)
2.26% less ownership
Funds ownership: 83.9% → 81.64% (-2.3%)
18% less capital invested
Capital invested by funds: $583M → $479M (-$104M)
36% less call options, than puts
Call options by funds: $462K | Put options by funds: $724K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.35M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$1.25M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
+$1.21M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.05M |
| 5 |
Millennium Management
New York
|
+$860K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.85M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.98M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$1.66M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$1.19M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$729K |
LXRX Hedge Fund Activity: Q4 2021 in Review
110 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2021, worth a combined $479M — down 18% from $583M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new LXRX positions and 10 closed out — a net gain of 14 holders — while 38 added to existing stakes and 29 trimmed.
The largest buyer was Dimensional Fund Advisors, adding an estimated $1.35M. The largest seller was Fidelity Investments, cutting an estimated $3.85M.
- 110 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2021, up from 96 in Q3 2021.
- Funds reported $479M of Lexicon Pharmaceuticals stock for Q4 2021, down 18% quarter-over-quarter.
- 24 funds opened new Lexicon Pharmaceuticals positions in Q4 2021 and 10 closed out, a net change of +14 holders.
- The largest Lexicon Pharmaceuticals buyer in Q4 2021 was Dimensional Fund Advisors, an estimated $1.35M added.
- The largest Lexicon Pharmaceuticals seller in Q4 2021 was Fidelity Investments, an estimated $3.85M sold.
Based on aggregated 13F filings for Q4 2021.